Parameter
| Biomarker | TNF-α | Full name | Tumor Necrosis Factor-α | Molecular Type | cell factor |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Inflammatory regulation, targeted therapy monitoring | ||
| Disease | Rheumatoid Arthritis (RA) | Disease Subtypes | / | ||
| Organ | Joint (Synovium) | Test Sample / Technology Platform | Serum, synovial fluid (ELISA, flow cytometry) | ||
| Pathobiological Mechanisms | The core pro-inflammatory factors secreted by synovial macrophages and T cells activate the NF-κB pathway, promoting the release of inflammatory factors and inducing synovial hyperplasia and bone erosion; this is a key target of TNF-α inhibitors. | ||||
| Clinical Availability Status | Widespread availability (assisted evaluation + target monitoring) | ||||
| Notes and Dynamics | Patients who achieved a serum level of TNF-α inhibitor <8 pg/mL after treatment showed a significant increase in ACR20 attainment rate, which can serve as an immediate monitoring indicator of therapeutic response. | ||||